Grifols SA (GRFS)
9.55
+0.46
(+5.06%)
USD |
NASDAQ |
Nov 14, 16:00
9.545
0.00 (0.00%)
After-Hours: 20:00
Grifols Cash and Short Term Investments (Quarterly): 901.05M for Sept. 30, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 901.05M |
| June 30, 2024 | 2.404B |
| December 31, 2023 | 713.78M |
| September 30, 2023 | 575.44M |
| June 30, 2023 | 605.57M |
| December 31, 2022 | 620.50M |
| June 30, 2022 | 586.17M |
| June 30, 2021 | 484.99M |
| March 31, 2021 | 453.74M |
| December 31, 2020 | 726.30M |
| September 30, 2020 | 1.227B |
| June 30, 2020 | 1.002B |
| March 31, 2020 | 717.72M |
| December 31, 2019 | 2.766B |
| September 30, 2019 | 869.70M |
| June 30, 2019 | 822.20M |
| March 31, 2019 | 847.80M |
| December 31, 2018 | 1.244B |
| September 30, 2018 | 736.01M |
| June 30, 2018 | 797.27M |
| March 31, 2018 | 1.057B |
| December 31, 2017 | 1.064B |
| September 30, 2017 | 973.68M |
| June 30, 2017 | 858.20M |
| March 31, 2017 | 801.29M |
| Date | Value |
|---|---|
| December 31, 2016 | 946.17M |
| September 30, 2016 | 1.012B |
| June 30, 2016 | 899.89M |
| March 31, 2016 | 1.143B |
| December 31, 2015 | 1.249B |
| September 30, 2015 | 1.004B |
| June 30, 2015 | 885.96M |
| March 31, 2015 | 864.67M |
| December 31, 2014 | 1.312B |
| September 30, 2014 | 1.165B |
| June 30, 2014 | 1.006B |
| March 31, 2014 | 942.22M |
| December 31, 2013 | 978.73M |
| September 30, 2013 | 659.59M |
| June 30, 2013 | 625.46M |
| March 31, 2013 | 519.60M |
| December 31, 2012 | 625.98M |
| September 30, 2012 | 518.27M |
| June 30, 2012 | 424.95M |
| March 31, 2012 | 258.45M |
| December 31, 2011 | 454.90M |
| September 30, 2011 | 254.19M |
| June 30, 2011 | 873.03M |
| December 31, 2010 | 335.94M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
453.74M
Minimum
Mar 2021
2.766B
Maximum
Dec 2019
984.62M
Average
715.75M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Cellectis SA | 260.89M |
| Adaptimmune Therapeutics PLC | 214.79M |
| Akari Therapeutics PLC | 4.177M |
| Biodexa Pharmaceuticals PLC | 6.394M |
| Verona Pharma PLC | 336.04M |